The Effect of Moderate CYP3A Inducer Rifabutin on the Pharmacokinetics of Zanubrutinib in Healthy Males
Completed · Phase 1
Conditions studied: Healthy, Male
In brief
The primary objective of this study was to determine the effect of the moderate cytochrome P450 3A (CYP3A) inducer rifabutin on the pharmacokinetics (PK) of zanubrutinib in healthy males.
Key facts
- Study ID
- NCT04470908
- Run by
- BeiGene
- People needed
- 13
- Starts
- 2020-07-29
- Expected to finish
- 2020-11-10
- Last updated by the study team
- 2024-10-26
Who can join
Age: 18 and older, up to 65. Sex: male. Healthy volunteers: accepted.
Where it is running
- Covance Clinical Research Unit — Daytona Beach, Florida, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.